Emergency Medicine: Open Access
Open Access

Emergency Drugs and Drug Therapy in Healthcare System

Alsaz Zaer^{* *}Correspondence: Alsaz Zaer, Department of Pharmacology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan, Email:

Author info »

Description

Emergency drugs are those medications which may be required to meet the instant therapeutic needs of patients and which are not available from any other ratified source in enough time to stop threat or harm to patients. There are two groups of emergency medications. The first category consists of medicines that are absolutely necessary and belong in every emergency medicine kit. Depending on the practitioner's background in emergency medical procedures and whether sedation and general anesthesia are used for behavior and anxiety management, the second category of medications consists of helpful but optional medications. Different offices will have different emergency drug kits. A dentist with more experience performing venipuncture and training to administer general and intravenous sedation would have more complete drug equipment. Optional medications that can be given orally, intramuscularly/sublingually, and intranasal will be discussed for dentists who are not skilled in venipuncture.

Everyone agrees that emergency medications must be easily accessible for dentists. Regarding the specific medications that ought to be included in an emergency kit, opinions vary. A dental office should have easy access to oxygen, epinephrine, nitroglycerin, injectable diphenhydramine or chlorpheniramine, albuterol, and aspirin. It's also important to take into account other medications like flumazenil, glucagon, atropine, ephedrine, hydrocortisone, morphine or nitrous oxide, naloxone, midazolam or lorazepam, and atropine. The level of training that dentists have in handling medical emergencies varies. The individual dentist who is in the best position to judge whether these agents are appropriate for the specific practice should therefore make the final decision.

Even with the best prevention measures in place, emergencies can still happen. Plans are required to handle these situations, and it's possible that the medications mentioned above will be necessary. They might prevent a fatality.

First-hand Emergency Drugs:

• Aminophylline

• Amphetamine sulfate

• Amyl nitrite inhalation

• Atropine sulfate

• Caffeine sodium benzoate

• Calcium Gluconate

• Chlorpheniramine

• Digoxin

• Diphenylhydantoin sodium

• Phenylephrine

Perhaps the most popular form of treatment for disorders is pharmacotherapy. It is harmful for the burdening patients and the healthcare system. Drug-Related Problems (DRPs), which are defined as an incident or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes, are a common cause of hospital admissions and Emergency Department (ED). At least a third of Drug-Related Hospital Admissions (DRAs), which have an average prevalence of 15% and 21%, appear to be preventable, according to two recent systematic studies. DRAs are thus a significant finding in fields of study that have a close connection to pharmacotherapy, like clinical pharmacy.

There is a lot of variation in the ways that DRAs are measured, and there aren't many proven technique. The methods are timeconsuming and expensive since they frequently entail evaluations by a professional panel of skilled doctors. The feasibility and Inter-Rater Reliability (IRR) is validated, but its accuracy that is, its sensitivity and specificity is unclear and it also necessitates the participation of an expert panel. People created and validated the Assessment Tool to Identify Hospital Admissions Related to Medication (AT-HARM10), a useful tool for locating potential DRAs. AT-HARM10, which is used to distinguish between admissions that are likely to be drug-related and those that might be.

A moderate to large IRR with accuracy measures between 70% and 86%. This has led to concerns about how it might be used to evaluate Emergency Department (ED) visits rather than only hospital admissions, and an updated version to make the tool easier to grasp has been sought. Drug resistance is still a significant barrier to cancer treatment. It is possible for resistance to develop from a subpopulation of cancer cells that initially resist drug therapy. Numerous investigations have identified a particular bypass pathway's activation as the crucial treatment target for avoiding medication tolerance. We use proteomics and genomes to evaluate the emergence of drug tolerance to Estimated Glomerular Filtration Rate (EGFR) inhibitors in lung adenocarcinoma cells with EGFR mutations and to BRAF inhibitors in melanoma cells with BRAF mutations. That numerous alternative mutagenic pathways, such as YAP, STAT3, IGFR1, and the phospholipase C (PLC)/protein kinase C (PKC) pathways are activated in both situations. Our findings indicate that rather than concentrating on a single specific pathway, an effective therapeutic approach to prevent drug tolerance will need to take into account a number of alternative mutagenic pathways.